Arcellx (ACLX) stock surged on Monday after announcing a $7.8 billion acquisition deal with Gilead Sciences (GILD). Gilead will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share. This acquisition builds on a previous collaboration between the two companies to develop Arcellx’s lead product candidate for multiple myeloma.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Arcellx Stock (ACLX) Rockets on a Massive Deal with Gilead Sciences (GILD)
Arcellx (ACLX) stock surged on Monday after announcing a $7.8 billion acquisition deal with Gilead Sciences (GILD). Gilead will acquire Arcellx for $115 per share in cash plus a contingent value right of $5 per share. This acquisition builds on a previous collaboration between the two companies to develop Arcellx’s lead product candidate for multiple myeloma.